Last updated: March 13, 2025
Sponsor: Mayo Clinic
Overall Status: Active - Recruiting
Phase
N/A
Condition
Platelet Disorders
Lymphoproliferative Disorders
Chronic Lymphocytic Leukemia
Treatment
Non-Interventional Study
Clinical Study ID
NCT06151730
23-007083
23-007083
NCI-2023-09519
All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Patients with chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL),Waldenstrom macroglobulinemia (WM), and marginal zone lymphoma (MZL), planned tobegin Bruton tyrosine kinase inhibitors (BTKi) treatment or who will start a newBTKi agent after a 5-day wash out period (either as a single agent or on combinationwith other chemotherapies), who are willing to return to Mayo Clinic for ongoingfollow-up
Exclusion
Exclusion Criteria:
- Patients with known central nervous system (CNS) involvement of their B-cellmalignancy
Study Design
Total Participants: 100
Treatment Group(s): 1
Primary Treatment: Non-Interventional Study
Phase:
Study Start date:
January 05, 2024
Estimated Completion Date:
December 01, 2025
Study Description
Connect with a study center
Mayo Clinic in Rochester
Rochester, Minnesota 55905
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.